| Literature DB >> 33808118 |
Tamy Colonetti1, Maria Laura R Uggioni1, Sarah D Ferraz1, Marina C Rocha1, Mateus V Cruz1, Maria Inês da Rosa1, Antonio J Grande2.
Abstract
BACKGROUND: Brain injury has several consequences throughout life, its increased incidence has caused great public concern. The aim was identifying the main nutritional therapies recommended for children with brain injuries.Entities:
Keywords: brain injuries; child; nutrition therapy
Year: 2021 PMID: 33808118 PMCID: PMC8066061 DOI: 10.3390/nu13041130
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flow diagram of information through the different phases of a systematic re-view.
Characteristics of the studies included.
| Author/Year | Country | Study Location | Total Population | Intervention Population | Gender | Age | Feeding Type | Aim of the Study |
|---|---|---|---|---|---|---|---|---|
| Andrew et al., 2017 [ | United Kingdom | Children’s Center | 32 | 14 | 28 M/12 F | 1–18 months | Oral or enteral | The aim of the study was to investigate whether nutritional intervention with supplementation of DHA, choline, and uridine at the maximum permitted levels improves the results of neurological development in infants with suspected CP. |
| Briassoulis et al., 2006 [ | Greece | Hospital- Pediatric intensive care unit | 40 | 20 | Uninformed | Average: 112 (months) | Enteral | Enteral feeding supplemented with glutamine, arginine, antioxidants, and omega-3 fatty acids in order to assess nutritional and metabolic indices and survival, length of stay, time of ventilation. |
| Dabydeen. et al., 2015 [ | United Kingdom | Uninformed | 16 | 8 | 9 M 7 F | 12 months | Oral | Follow-up study 12 months after acute perinatal brain injury with a high-calorie and high-protein diet, in weight and height. |
| Meinert et al., 2018 [ | USA | Uninformed | 90 | 85 divided into 3 groups: Group 2 = 32; Group 3 | Uninformed | Uninformed | Enteral | The authors sought to assess the time of onset of nutritional support and mortality. |
| Merhar et al., 2015 [ | USA | Hospital | 24 | 13 | 15 M 9 F | Uninformed | Enteral | A study evaluated the use of protein supplementation in children with CP for 12 months to maintain adequate weight gain. Children were weighed every 2 weeks and had adjusted doses (4 g/kg/day). Tolerance, bicarbonate levels, blood urea were also evaluated. |
| Miyazawa et al., 2008 [ | Japan | Hospital | 18 | 9 | 16 M 2 F | 11.7 ± 4.4 years | Enteral nasogastric | A study evaluated the use of high amounts of pectin and low amounts of pectin to control GERD in children with CP. Assessment number of vomiting, residual gastric volume, esophageal pH. |
| Savage et al., 2015 [ | Australia | Hospital | 13 | 7 | 8 M 5 F | 7.2 years [CI 2.4–15.4 years] | Enteral via gastrostomy and nasogastric | A study sought to determine whether whey-based versus casein-based enteral formulas reduce reflux and accelerate gastric emptying in children with severe CP enteral feeding. He also evaluated the effect of these formulas on symptoms of low food tolerance such as choking, regurgitation, irritability, pain, and constipation. |
Figure 2Risk of Bias of randomized clinical trials included in the study.
Main outcomes.
| Author/Year | Intervention/Dose | Evaluated Outcomes | Supplementation Characteristics | Main Results | Authors’ Conclusions |
|---|---|---|---|---|---|
|
Andrew et al., 2017 [ | The babies received docosahexaenoic acid (DHA), choline and uridine-5-monophosphate (UMP), 2 g/kg/day (maximum 24 g/day), supplied as a combination of 2 g, 3 g and 12 g sachets, for 2 years or while complying with the study protocol. | Neurodevelopment of neonates was assessed by the Bayley-III is a standardized measure of neurodevelopment suitable for children aged 1 to 42 months with cognitive, language, and motor domains. | Participants received daily treatment for 2 years. | The Cognitive composite score of the Bayley Scales of Infant and Toddler Development, Third Edition (CCS Bayley-III) treatment group was not significantly larger than the comparison group (mean 77.7 [SD 19.2] and 72.2 [SD 19.8] | No statistically significant differences were identified in the result of neurological development between the treatment and comparison groups. |
|
Briassoulis et al., 2006 [ | Enteral feeding supplemented with glutamine, arginine, antioxidants and omega-3 fatty acids | Nutritional and metabolic indices; survival, length of stay, ventilation time. The severity of the head injury was assessed by the Glasgow Coma Scale, and the severity of illness was assessed by the Pediatric Risk of Mortality (PRISM) score, the simplified Therapeutic Intervention Scoring System (TISS), and indices of organ failure. Multiple organ system failures were defined using the criteria by Wilkinson. Caloric intake was calculated daily from the patients’ flow sheets. In each group, were calculated the differences of caloric intake-PBMR, caloric intake–predicted energy expenditure, and dactual caloric or protein intake–initially estimated caloric or protein difference. | Of the 40 mechanically ventilated children with severe head trauma, 20 were in the intervention group using Stresson (N. V. NUTRICIA, Zoetermeer, The Netherlands), an enteral food supplemented with glutamine, arginine, antioxidants and omega-3 fatty acids and 20 were in the control group that used Tentrini (N. V. NUTRICIA), an enteral formula specifically modified for critically ill children. | Only interleukin -8 levels were lower in the intervention group compared to the regular formula group on day 5 (23.6 1.5 vs. 35.5 4 pg/mL, | Although immunonutrition can decrease interleukin-8 and gastric colonization in children with severe TBI, it may not be associated with additional advantage over that demonstrated by regular early enteral nutrition. |
|
Dabydeen et al., 2015 [ | 120% of the EAR for energy in the first 6 months and 101% in the 6 months after. | Brain and body growth rate. Measurements were made at baseline (term) and final measurements at 12 months; intermediate measurements were also made to provide information on the pattern of growth in the first 12 months. Head circumference and weight were, therefore, also measured at 3 monthly intervals, corticospinal tract axonal diameter was also estimated at 4 and 8 months, and the length was also measured at 6 months. SD (z) scores for anthropometric measures, derived from the British 1990 growth reference, which was revised in September 1996, were used so that age and gender data could be combined. Weight was measured to the nearest 10 g, with the child unclothed, by using a portable digital electronic scale. The length was measured using a horizontal stadiometer accurate to 1 cm. For both weight and length, 3 measurements were made, and the mean was calcu- lated. | All children were fed orally. For both groups, the goal of their protein/energy ratio was 2.5 g/420 kJ (100 kcal) to 3.6 g/420 kJ (100 kcal). | The study ended in the first analysis, when the 16 subjects completed the protocol, since the predetermined stop criterion of 1 SD difference in occipitofrontal circumference at 12 months of age corrected in those who received the high energy and protein diet was demonstrated. Axonal diameters in the corticospinal tract ( | The results show that babies with significant perinatal brain damage increased nutritional needs in the first postnatal year and suggest that decreased postnatal brain growth may exacerbate their deficiency. |
|
Meinert et al., 2018 [ | Children were divided into 4 groups according to the time to start nutritional support and hypothermia or normothermia. Group 1—without nutritional support during the study period; Group 2—nutritional support started <48 hours after the injury; Group 3—nutritional support started 48 h–<72 h after the injury; Group 4—nutritional support started 72 h–168 h after injury. | Glasgow Mortality and Outcome Scale. | The characteristics of the diet are not described in the study, only the period of the beginning of the diet and its outcomes were evaluated. | The beginning of nutrition before 72 h was associated with survival between Group 1 and Groups 2 and 3 were statistically significant ( | The beginning of nutritional support before 72 hours after TBI was associated with decreased mortality and a favorable outcome in this analysis. |
|
Merhar et al., 2015 [ | Use of 4 g/kg/d or a maximum of 30 g of protein per day | weight gain, growth, and tolerance. Growth parameters were followed as per usual clinical practice while infants were inpatients in the NICU, with head circumference and length measured once a week and weight measured daily by the patient’s bedside nurse. After discharge, weight, length, and head circumference were measured by an examiner blinded to the patient’s study group at 3 months (±2 weeks) of age. Measurements were done on the same scale and length board for all participants in our NICU follow-up clinic. | A high-protein diet was offered to members of the high-protein group that achieved complete enteral nutrition (of at least 130 mL/kg/d), protein was added to the diet to bring them to a target of 4 g/kg/d of protein, with a maximum of 30 g of protein per day. | Whey protein powder was well tolerated by 9 of the 13 children in the high-dose protein group, and no adverse events related to the supplement were seen. The protein group had higher serum urea nitrogen levels at 10 ( | Protein supplementation maintained the growth rate in infants with brain damage. Whey protein supplementation can potentially contribute to tissue growth and repair after brain injury. There was no difference between the two groups in birth weight at birth, however at 3 months of age the control group had a significant decrease in weight, while the protein group maintained a weight within the recommended values. |
|
Miyazawa et al., 2008 [ | Pectin supplementation in two dosages: 2:1 high pectin (Group A) and 3:1 low pectin (Group B) | Gastroesophageal reflux (GER).In the first part of this study, esophageal pH monitoring was performed over 48 hours for each subject. A single crystal antimony multi-use pH catheter with two channels [the end of the catheter, and 7 cm (5 cm for two patients under 6 years of age) above the end] was placed and connected to a portable digital data recorder. In the second part of the study, to elucidate the clinical effects of pectin liquid on GERD symptoms, four patients in group A were fed with a high-pectin diet for 4 weeks, followed by a non-pectin diet for 4 weeks. Five other patients were fed in reverse order. Nine patients in group B were fed with a low-pectin or non-pectin diet. | They received the enteral formula through a nasogastric tube. Group A patients were fed the enteral formula, including a high concentration of pectin liquid [enteral formula: pectin liquid = 2:1. Group B received a low pectin diet [enteric formula: pectin liquid = 3:1)] or non-pectin diet. The composition of the enteric formula per 100 mL was 100 kcal, 4.5 g protein, 16 g carbohydrate, and 2.7 g lipid. The composition of the pectin liquid per 100 mL was 9 kcal, 0.2 g protein, 0.6 g carbohydrate, 0.1 g lipid, and 76 mg sodium. | The mean value for pH% of time <4 in the lower and upper esophagus was significantly reduced with a diet rich in pectin [9.2% (6.2–22.6) vs. 5.0% (3.1–13.1); | He observed that liquid pectin can help and improve the reduction of vomiting episodes, respiratory symptoms, and gastroesophageal reflux in children with CP, and can be considered an alternative therapy for gastroesophageal reflux disease in these patients. |
|
Savage et al., 2015 [ | Comparison of the use of three protein components. Casein-based enteric formula [82% casein, | Reflux and gastrointestinal symptoms. On day 6 of each week, GE rate was measured using the 13C-Na-octanoate breath test using 13C-labeled Na-octanoate (50 mg, 99% enrichment). Patients were fasted overnight and then given a 200-mL bolus of either the casein or whey formula containing 100 mg 13C-Na-octanoate for breath test measurement of liquid GE. Breath samples were taken using a small flexible tube connected to a syringe, which was held in close proximity to the patient’s mouth or nose as he or she breathed out. Samples were taken before the bolus and afterward at 5-min intervals until 30-min and 15-min intervals until 4 h. Patients remained recumbent in their wheelchair, in a pram, or on a hospital bed for the 4-h study period. Breath samples were analyzed for 13CO2 content using an isotope ratio mass spectrometer, and the 13CO2 excretion rate curves were used to calculate the gastric half-emptying time (GE t1/2) using an established nonlinear regression model. Age-related reference ranges20 for liquid GE t1/2 were then used to compare GE with various formulas. | The patients acted as their own controls and the children were divided into three groups where they received for a week: standard casein-based enteric formula (Pediasure [82% casein, 18% whey); Abbott Australasia, NSW, Australia) or 50% whey, 50% casein Formula (50% WWP) (Nutren Junior; Nestlé Clinical Nutrition, Vevey, Switzerland) or 100% partially hydrolyzed whey protein (100% WPHP) formula (Peptamen Junior; Nestlé Clinical Nutrition). | Whey formulas emptied significantly faster than casein ( | In children with severe CP with gastrostomy, gastric emptying of the whey-based enteric formula is significantly faster than casein. The acceleration in gastric emptying does not change the frequency of gastroesophageal reflux, and there seems to be no effect of whey versus casein in reducing episodes of acid, non-acid, and total reflux. The results indicate that the selection of enteral formula may be particularly important for children with severe CP and delayed gastric emptying. |
|
Staiano et al., 2000 [ | Supplementation of 100 mg/kg of glucomannan 2× daily or placebo (both 500 mg capsules) | Chronic constipation in children with severe brain injury. Weekly defecation frequency, total gastrointestinal transit time, colonic segmental transit time, and anorectal manometry were evaluated in all patients, before and after treatment. In brief, total gastrointestinal transit time was assessed by means of 20 polyethylene radiopaque markers (5-mm diameter), swallowed with a milk breakfast. The feces from each subsequent bowel movement were collected and radiographed to evaluate the presence and number of radiopaque markers until excretion of at least 80% of the markers was documented. Colonic segmental transit time was evaluated by using a plain abdominal radiograph performed after 24 h from the last ingestion of 3 sets of 20 distinctive markers (ring, cylinder, and linear) taken on 3 consecutive days. The 3 types of markers were always ingested in the same sequence. | The patients were divided into treatment with glucomannan 100 mg/kg twice daily or placebo. An oral dose was administered by mixing the contents of a 500 mg capsule with 100 mL of water; the result was a solution containing glucomannan in the final concentration of 5 mg/ml, | The group using glucomannan significantly increased ( | An increase in the frequency of evacuation was observed for the intervention group. Laxative use reduced in the intervention group. There was also an improvement in the consistency of evacuation with reduced pain when defecating in the intervention group compared to the control group. In children with neurological problems, glucomannan had a beneficial effect only on bowel habits and not on gastrointestinal transit time. |